health
New Paper Offers Practical Roadmap for Using Real-World Data in FDA Drug Approvals and Label Expansions
BLUEBELL, Pa.--(BUSINESS WIRE)--Slipstream co-authors a new CPT paper with practical guidance for using real-world data in FDA drug approvals and label expansions.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Should naloxone kits be available in public places with defibrillators?
Sootoday
Four things you need to know about deprescribing | Folio
University Of Alberta
Blood test detects breast cancer more than a year before scans
The Brighter Side of News
.jpeg;w=960;h=640;mode=crop)
Parents urged to ask about RSV immunization for eligible infants
Barrie News
London doctors perform Canada's first ‘heart in a box’ transplant
London Free Press